Market capitalization | $8.71b |
Enterprise Value | $8.73b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.59 |
P/S ratio (TTM) P/S ratio | 12.56 |
P/B ratio (TTM) P/B ratio | 159.13 |
Revenue growth (TTM) Revenue growth | 30.38% |
Revenue (TTM) Revenue | $693.40m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
11 Analysts have issued a Tempus AI forecast:
11 Analysts have issued a Tempus AI forecast:
Dec '24 |
+/-
%
|
||
Revenue | 693 693 |
30%
30%
|
|
Gross Profit | 369 369 |
33%
33%
|
|
EBITDA | -651 -651 |
300%
300%
|
EBIT (Operating Income) EBIT | -688 -688 |
251%
251%
|
Net Profit | -706 -706 |
230%
230%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.
Head office | United States |
CEO | Eric Lefkofsky |
Employees | 2,400 |
Website | www.tempus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.